Informa Training Partners Changes Name to Red Nucleus Boston


Red Nucleus logo

Red Nucleus

“The name change solidifies a stronger presence for Red Nucleus in one of the fastest growing life sciences learning markets in the world.” Ian Kelly, President and CEO of Red Nucleus.

Red Nucleus, a leading provider of strategic learning, performance, and process solutions for the life sciences industry, today announced that Informa Training Partners, a life sciences training company acquired by Red Nucleus in October 2019, is officially changing its name to Red Nucleus Boston, effective immediately.

“The name change solidifies a stronger presence for Red Nucleus in one of the fastest growing life sciences learning markets in the world,” said Ian Kelly, President and CEO of Red Nucleus. “Informa Training Partners had been a long-time competitor. Joining forces with them last fall has been a strategic enhancement to our company’s mission to deliver our clients the very best resources in life sciences sales training programs. Our combined industry experience spans more than 50 years. We are pleased to have added their talent, innovation, and expertise in the learning space to our leading brand and are happy to officially call them Red Nucleus Boston.”

Red Nucleus is a full-service provider of learning and process solutions for the life sciences industry. Through the company’s best-in-class approach, technologies, and team, Red Nucleus designs and produces global solutions, including e-learning modules, mobile applications, virtual preceptorships, print modules and job aids, workshop design and facilitation, video production and games, as well as various consultative services. In addition, the Red Nucleus R&D team, located in Malvern, PA, delivers expert capabilities including R&D Strategy & Change, System & Information Management, and overall R&D Operational Services. Red Nucleus’ Commercial and R&D market share has grown tremendously in the last several years, sparking transformational learning experiences and R&D systems management excellence among biotech, biopharmaceutical, and medical device companies in the US, Europe, India, and Japan.

The name change announced today for the Boston office is part of Red Nucleus’ vision to deepen its expert training competencies and continue the company’s keen focus to stay on top of trends and evolutions in the healthcare industry. “I am happy to publicly announce Red Nucleus Boston and extend our presence and support our combined client base in this strategic market,” added Kelly. “Our unwavering commitment to success is only getting stronger.”

“We are thrilled to be a part of the Red Nucleus family,” said Eileen Mathews, Informa’s Vice President of Client Services. “Combining our more than 50 years of industry expertise will allow us to support both RN’s existing clients and legacy Informa clients to continue to provide stellar customer service. Our goal will be to continue to provide best-in-class training to all of our clients, with expanded capabilities and resources.”

About Red Nucleus

Red Nucleus is the premier provider of strategic learning, performance, and process solutions exclusively for the life sciences industry. Our global solutions engage and inspire teams across the commercial and R&D spaces and are designed to boost understanding, efficacy, and compliance.

Squarely focused on the life sciences industry for close to 30 years, Red Nucleus takes pride in our long-term relationships with industry leaders, as well as our strategic partnerships with innovative startups. We are focused on developing thoughtful, high- quality solutions that are in accordance with each client’s unique culture and process. Our clients trust us to build impactful, award-winning programs that deliver actionable insights and measurable results.

Red Nucleus is headquartered in Yardley, PA. The Red Nucleus R&D office is located in Malvern, PA. The company also has offices in Boston, MA, the United Kingdom, India, and Japan.

Visit http://www.rednucleus.com to learn more

Share article on social media or email:

Leave a Reply